Watch MREO. Know when insiders buy.
One email the day a filing lands. Free.
MREO
Mereo BioPharma Group plc
0.30
+0.01 +4.48%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
87
PASS · shorts 87
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $241.9MP/E —DIV YIELD —FCF YIELD -10.48%REV TTM —NET INCOME −$28.1MNET CASH —52W 0.24 – 2.31SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$7M | −$7M | — | -0.01 | −$6M | $0 | −$6M | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$8.8M | −$6.7M | — | -0.01 | −$4.3M | $0 | −$4.3M | Aug 11 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$8.4M | −$7.4M | — | -0.01 | −$7.7M | $0 | −$7.7M | Mar 19 |
| Q3 2025 · Sep 30 | $0 | — | — | −$10M | −$7M | — | -0.01 | −$7.3M | $0 | −$7.3M | Nov 10 |
| Q2 2025 · Jun 30 | $500K | — | — | −$10.5M | −$14.6M | — | -0.02 | −$7.7M | $0 | −$7.7M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$11.2M | −$12.9M | — | -0.02 | −$8.3M | $20K | −$8.3M | Aug 11 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$15.3M | −$7M | — | -0.01 | −$9.4M | $0 | −$9.4M | Mar 19 |
| Q3 2024 · Sep 30 | $0 | — | — | −$9.4M | −$15M | — | -0.02 | −$7.5M | $0 | −$7.5M | Nov 10 |
| Q2 2024 · Jun 30 | $0 | — | — | −$12.8M | −$12.3M | — | -0.02 | −$7.9M | $0 | −$7.9M | Nov 10 |
| Q1 2024 · Mar 31 | $0 | — | — | −$9.9M | −$9M | — | -0.01 | −$8M | $0 | −$8M | Nov 10 |
| Q4 2023 · Dec 31derived | $1M | — | — | −$7.1M | −$9.1M | — | -0.01 | −$6.8M | — | — | Mar 26 |
| Q3 2023 · Sep 30 | $0 | — | — | −$9.1M | −$6.5M | — | -0.01 | $2.7M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $500K | — | −$40.1M | −$41.9M | -8375.6% | -0.05 | −$31M | $20K | −$31M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$47.4M | −$43.3M | — | -0.06 | −$32.8M | $0 | −$32.8M | — | — |
| FY2023 · to Dec 31 | $10M | — | −$28.4M | −$29.5M | -294.7% | -0.04 | −$21.1M | $0 | −$21.1M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$54.4M | −$42.2M | — | -0.07 | −$48.8M | $13K | −$48.8M | — | — |
Every number comes from Mereo BioPharma Group plc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.